Curevo Vaccine logo

Curevo Vaccine

A clinical-stage biotech company developing amezosvatein, a vaccine for shingles and chickenpox.

44 employees · est. 2017 · Bothell, United States

VS
Valneva logo

Valneva

Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya

637 employees · est. 2013 · Saint-herblain, France

Valneva is the older company (2017 vs 2013); Valneva is the larger of the two.

Side-by-Side Comparison

Curevo Vaccine Valneva
Founded
2017 2013 older
Headquarters
Bothell, United States Saint-herblain, France
Employees
44 637 larger
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health Care, Health and Wellness
Funding Stage
Acquired Grant
Total Funding
$196.00M $720.10M
Funding Rounds
4 15
Services
Development of next-generation non-mRNA vaccines, Clinical trials for vaccine efficacy and safety, Comparative studies with existing vaccines, Improving tolerability and accessibility of vaccines Vaccine Research and Development, Manufacturing of Vaccines, Commercialization of Vaccines, Marketing and Distribution
Target Customers
Individuals susceptible to shingles and chickenpox, Immunocompromised patients, particularly children, Healthcare providers and institutions, Global health organizations and vaccine distributors Healthcare Providers, Travelers, Health Organizations, Governments, Investors
Taxonomy
Biotech, Vaccine Development, Clinical-Stage Biotech, Amezosvatein, Herpes Zoster Vaccine, Chickenpox Vaccine, Shingles Vaccine, Varicella Zoster Virus, Adjuvanted Subunit Vaccine, Immunology, Drug Development, Reactogenicity Improvement, Public Health, Infectious Disease, Clinical Trials Specialty Vaccines, Infectious Disease Prevention, Prophylactic Vaccines, Vaccine Modalities, First-in-Class Vaccines, Only-in-Class Vaccines, Lyme Disease Vaccine, Chikungunya Vaccine, Travel Vaccines, Vaccine R&D, Vaccine Manufacturing, Clinical Development, Public Health Threats, Pfizer Partnership, Zika Virus Vaccine
Website
curevovaccine.com valneva.com
Curevo Vaccine logo

About Curevo Vaccine

Curevo Vaccine, founded in 2017, is a clinical-stage biotech company based in the United States. Specializing in the development of vaccines for varicella and herpes zoster, the company is advancing its flagship product, Amezosvatein (CRV-101), a non-mRNA, adjuvanted subunit vaccine aimed at prevent...

Valneva logo

About Valneva

Valneva, founded in 2013, is a France-based specialty vaccine company renowned for addressing infectious diseases with significant unmet needs. With a forward-thinking approach, the company prides itself on offering first-, best-, or only-in-class vaccine solutions. Their portfolio includes the worl...

We will tell you when either one moves

BounceWatch watches Curevo Vaccine and Valneva for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Curevo Vaccine and Valneva — by email.

Frequently Asked Questions

Curevo Vaccine — A clinical-stage biotech company developing amezosvatein, a vaccine for shingles and chickenpox.. Valneva — Specialty vaccine company focused on prevention of infectious diseases with major unmet need, such as Lyme & chikungunya. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Curevo Vaccine has raised $196.00M while Valneva has raised $720.10M.
Curevo Vaccine and Valneva operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Curevo Vaccine with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Curevo Vaccine on 11 Mar 2026, and Valneva on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy